

IA4PH 25/10/2024

# Synthetic data for microsimulation of cancer

Maikol Diasparra, PhD

Microsimulation Analyst  
Health Analysis Division  
Statistics Canada

# Introduction to Microsimulation

## Definition

Microsimulation involves modeling individual units (e.g., patients) to predict outcomes.

## Use in Healthcare

It's applied to simulate disease progression, treatment outcomes, and health economics.

## Why It Matters

Allows for detailed and personalized predictions to aid healthcare decision-making.

# Why Use Synthetic Data in Microsimulation?

**Definition:** Synthetic data is artificially generated data that mimics real-world datasets without exposing real patient information.

## Advantages:

- **Data Privacy:** Protects sensitive patient information.
- **Data Availability:** Fills gaps when real data is scarce or incomplete.
- **Scenario Testing:** Allows for the exploration of hypothetical or extreme cases without ethical concerns.

# Generating Synthetic Data for Microsimulation

## Process:


- 1. Model Development:** Define rules and distributions that represent real-world cancer data.
- 2. Data Simulation:** Use algorithms to generate synthetic datasets that reflect real-world characteristics.
- 3. Validation:** Ensure that synthetic data mirrors real data in terms of key metrics like incidence and outcomes.

## Challenges and Considerations:

- **Computational Resources, Bias and Uncertainty**

# OncoSim

- Free, web-based cancer microsimulation tool
- Co-developed by CPAC and Statistics Canada
- Models breast, colorectal, lung and cervical cancers and related screening programs in detail
- Also provides high-level projections for 30+ cancer sites
- Projects health and economic outcomes and attributes them to 19 risk factors



# How OncoSim works

## Data

Inputs represent Canadian population and reflect disease progression, treatment pathways and costs in Canada.

## Sources:

- Canadian Cancer Registry,
- Canadian Community Health Surveys
- Official Demography Stats
- Healthcare admin data
- Clinical trial results
- Expert opinion

## Verification process

- Calibration
- Internal and external validation
- Cross-model validation

## Customizable assumptions

Users can modify the existing inputs and assumptions to answer questions.




## Insights

OncoSim projects provincial and national-level estimates:  
E.g., # eligible for screening,  
# screening tests  
# colonoscopies  
# biopsies  
cancer incidence, mortality,  
costs, etc.

# Example 1: Lung cancer screening

## Program Volume

- Starting lung cancer screening at 50 or younger requires few additional screening resources because few additional individuals meet the eligibility criteria.
- Starting earlier could save more lives by encouraging earlier smoking cessation, contingent on quit rates among those who are ineligible for screening but are still referred to smoking cessation intervention.



**Note:**  
 ¹ Annual average over the next 10 years, 2024-2033. Assumptions: 40% recruitment rate, 70% rescreen rate, and 5-year phase-in period.  
 ² Lifetime outcomes of a cohort born in 1950-1998, Screening vs. No Screening  
 ³ Using 1.5% in 6 years risk threshold (PLCO-2L risk calculator)




# Example 2:

## Clinical impact of LDCT screening in Canada

Lung cancer screening could detect lung cancer earlier and prevent lung cancer deaths.

Compared to no screening, lung cancer screening in high-risk individuals cost <\$25,000 per QALY gained and was cost-effective.\*



\*At the conventional cost-effectiveness threshold of \$50,000 per QALY gained.



# Conclusion

- Synthetic data plays a crucial role in enhancing the flexibility and privacy of microsimulation models.
- It enables researchers and policymakers to explore a wide range of healthcare scenarios without compromising real patient data.
- Future directions for synthetic data in cancer modelling include the use of advanced algorithms to generate more sophisticated synthetic datasets.

# Getting involved?

If you think OncoSim has potential to support your work in cancer control, contact CPAC to get access

- [oncosim@partnershipagainstcancer.ca](mailto:oncosim@partnershipagainstcancer.ca)
- <https://www.partnershipagainstcancer.ca/tools/oncosim/>

OncoSim is led and supported by the Canadian Partnership Against Cancer, with model development by Statistics Canada, and is made possible through funding by Health Canada.



# Thanks!

[maikol.diasparra@statcan.gc.ca](mailto:maikol.diasparra@statcan.gc.ca)



Statistics  
Canada

Statistique  
Canada

Canada

